Dianthus Therapeutics, Inc.
DNTH
Classement en actions
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prix de l'action
$75.21
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$4.21B
Changement (1 jour)
4.33%
Changement (1 an)
108.93%
Pays
US
Échange Dianthus Therapeutics, Inc. (DNTH)
Catégorie
Healthcare
Ratio P/S pour Dianthus Therapeutics, Inc. (DNTH)
Ratio P/S au October 2026 TTM : 2.20K
Selon les derniers rapports financiers et le cours de l'action de Dianthus Therapeutics, Inc., le ratio cours/ventes actuel (TTM) est 2.20K. À la fin de 2023, le ratio P/S était de 18.97.
Historique du ratio P/S pour Dianthus Therapeutics, Inc. de 2016 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
